Annular psoriasis is a less frequently encountered morphological variant of pediatric psoriasis that may be misdiagnosed because of its clinical overlap with other annular conditions. We report a case of a 9-year-old girl who presented with generalized annular erythematous plaques with silvery scales involving >10% body surface area (BSA). Despite 12 months of optimized topical therapy, the disease progressed to >50% BSA, with scalp, facial, and nail involvement. Histopathological findings confirmed psoriasis. Ixekizumab was initiated with an 80-mg subcutaneous loading dose followed by 40 mg every 4 weeks, resulting in complete clearance of skin and nail lesions at 3 months, with only residual post-inflammatory hypopigmentation and no reported adverse events. This case highlights the potential for rapid progression of pediatric annular psoriasis and supports ixekizumab as an effective and well-tolerated treatment option for severe disease refractory to topical therapy.